B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression

YouweiLu; FengyingWu; QiuyiCaoYuSunMoliHuangJingXiaoBinZhouLiangZhang

首页> 外文期刊>Oncogene >B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression

【24h】

B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression

机译：B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Abstract PD-1/PD-L1 inhibitors have shown clinical benefit in lung adenocarcinoma (LUAD). However, the immunotherapy strategy is less effective in patients with EGFR-activating mutations (EGFR MT). Studies showed that besides low expression of PD-L1, the absence of TILs and distinct expression profile of immune checkpoint molecules might be associated with low response of the patient subset. In this study, we first compared CD8A, GZMB and PRF1 mRNA levels in different LUAD subtypes harboring different driver mutations by dataset analyses and investigated the association between 15 well-defined B7–CD28 family members and driver mutations. The results showed that the decreases in the density and function of CD8+ TILs, CD274 (PD-L1 gene), and CD86 and increases in VTCN1 (B7–H4 gene) and HHLA2 were associated with LUAD with EGFR-activating mutations. Immunohistochemical staining studies further supported that PD-L1 was downregulated and B7–H4 was upregulated in the subtype. Furthermore, PD-L1 expression was positively associated with levels of CD8A and granzyme B, while B7–H4 expression was negatively associated with granzyme B levels. In lung cancer cell lines, EGFR-activating mutations effectively upregulated B7–H4 and downregulated PD-L1. MEK/ERK-pathway activation upregulated B7–H4, and PI3K/Akt activation upregulated PD-L1. EGFR 19Del mutation was associated with inhibition of CD8+ T-cell function, while knocking down B7–H4 could reverse the inhibition, and further showed tumor-growth inhibition and longer survival in vivo. Taken together, this study shed light on that B7–H4 might be an alternative immune-checkpoint molecule and a potential therapeutic target for LUAD with EGFR MT.

著录项

来源
《Oncogene》 |2022年第5期|704-717|共14页
作者
YouweiLu; FengyingWu; QiuyiCaoYuSunMoliHuangJingXiaoBinZhouLiangZhang;
展开▼
作者单位

College of Pharmaceutical Sciences, Soochow University;

Department of Medical Oncology,Shanghai Pulmonary Hospital, Tongji University School of Medicine;

Department of Bioinformatics, School of Biology & Basic Medical Sciences,Soochow UniversityCentral Laboratory, Songgang People’s Hospital of Shenzhen Baoan DistrictJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词

B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression

摘要

著录项

相关主题

期刊订阅